Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

Group 1 - Wall Street is focusing on U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as potential beneficiaries following Pfizer's agreement with the Trump administration to reduce drug prices [1]